ストックスクリーナーアプリを入手
27.43
3.31%
0.88
アフターアワーズ：
27.65
0.22
+0.80%
前日終値:
$26.55
開ける：
$26.885
24時間の取引高:
1.58M
Relative Volume:
1.16
時価総額：
$5.58B
収益：
-
当期純損益:
$-464.20M
株価収益率:
-10.23
EPS:
-2.6823
ネットキャッシュフロー:
$-423.09M
1週間 パフォーマンス:
+10.92%
1か月 パフォーマンス:
+12.37%
6か月 パフォーマンス:
+52.98%
1年 パフォーマンス:
+77.37%
1日の値動き範囲:
$26.49
$27.63
1週間の範囲:
$24.36
$27.63
52週間の値動き範囲:
$13.36
$29.25
Immunovant Inc Stock (IMVT) Company Profile
Compare IMVT vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
27.43 | 5.40B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-20 | 開始されました | Bernstein | Mkt Perform |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 開始されました | Truist | Hold |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-03-03 | 開始されました | Jefferies | Hold |
| 2025-01-03 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-10-09 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-28 | 開始されました | Oppenheimer | Outperform |
| 2024-03-13 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | JP Morgan | Overweight |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-13 | アップグレード | UBS | Neutral → Buy |
| 2023-09-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 開始されました | BofA Securities | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-31 | 開始されました | Piper Sandler | Overweight |
| 2023-03-30 | 開始されました | Stifel | Buy |
| 2023-02-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-01-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2021-08-03 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-06-01 | ダウングレード | Stifel | Buy → Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-12 | 開始されました | Guggenheim | Buy |
| 2020-10-08 | 開始されました | Stifel | Buy |
| 2020-10-02 | 開始されました | Credit Suisse | Outperform |
| 2020-08-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-07-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-24 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Immunovant Inc (IMVT) 最新ニュース
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up - TipRanks
Immunovant (IMVT) CTO stout sells $251k in shares By Investing.com - Investing.com Canada
Van Tuyl, Immunovant’s chief legal officer, sells $128k in IMVT stock - Investing.com
Immunovant (IMVT) CTO stout sells $251k in shares - Investing.com
Immunovant (IMVT) CLO sells 5,165 shares to cover RSU tax bill - Stock Titan
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
Immunovant (NASDAQ: IMVT) CTO sells 10,132 shares for RSU tax obligations - Stock Titan
(IMVT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Immunovant (IMVT) grants director Frank Torti RSUs and stock options - Stock Titan
Immunovant (IMVT) director receives RSU and stock option grants - Stock Titan
Immunovant (IMVT) grants director Douglas J. Hughes RSUs and stock options - Stock Titan
Immunovant (IMVT) director granted options and RSUs in new equity awards - Stock Titan
Immunovant (IMVT) awards RSUs and stock options to director Jake Bauer - Stock Titan
Immunovant (IMVT) director receives 13,880 RSUs and 7,061 options - Stock Titan
Immunovant (IMVT) COO receives new stock options and RSU grants - Stock Titan
Immunovant (IMVT) CTO granted 96,851 options and 66,937 RSUs - Stock Titan
Immunovant (IMVT) CLO receives 59,820 options and 41,343 RSUs - Stock Titan
Immunovant (IMVT) CEO awarded new stock options and RSUs in equity grant - Stock Titan
Immunovant (IMVT) CFO awarded RSUs and 94,002 options under 2019 plan - Stock Titan
Immunovant falls on late-stage trial setback for TED therapy - MSN
Wolfe Research Maintains Immunovant(IMVT.US) With Buy Rating, Announces Target Price $47 - Moomoo
IMVT Shares Drop 2.4% After Batoclimab Fails to Meet Key Goals in Final-Stage Trial - Bitget
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - Yahoo Finance
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $42 - Moomoo
Immunovant Inc stock: Why biotech investors are watching this closely now - AD HOC NEWS
Aberdeen Group plc Increases Stake in Immunovant, Inc. $IMVT - MarketBeat
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Immunovant (NASDAQ:IMVT) CEO Sells $342,918.90 in Stock - MarketBeat
Immunovant (IMVT) CEO Venker sells $342,854 in shares By Investing.com - Investing.com India
Immunovant (IMVT) CEO Venker sells $342,854 in shares - Investing.com
Immunovant (IMVT) CEO settles CVARs into 368,750 shares, disposes stock - Stock Titan
Alto Neuroscience, Immunovant And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Truist reiterates Hold on Immunovant stock after trial failure By Investing.com - Investing.com India
Immunovant's treatment for eye disease fails in late-stage trials - Reuters
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data UpdateSlideshow - Seeking Alpha
IMVT: Brepocitinib advances into pivotal LPP trials as batoclimab's TED study informs Graves' strategy - TradingView
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP - Yahoo Finance
Leerink cuts Immunovant stock price target on failed TED trial By Investing.com - Investing.com Australia
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM - BioPharma Dive
Leerink cuts Immunovant stock price target on failed TED trial - Investing.com
Oppenheimer maintains Immunovant stock rating on next-gen drug focus By Investing.com - Investing.com India
Oppenheimer maintains Immunovant stock rating on next-gen drug focus - Investing.com UK
IMVT: Batoclimab missed its Phase 3 endpoint in thyroid eye disease; focus shifts to IMVT-1402 - TradingView
Immunovant Inc (IMVT) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):